Sequencing Agents in Prostate Cancer

April 15, 2014
Daniel P. Petrylak, MD

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses sequencing agents in prostate cancer.

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, discusses sequencing agents in prostate cancer.

Clinical Pearls:

  • Agents such as enzalutamide, abiraterone, and radium-223, are now FDA-approved and proven to improve survival
  • Physicians sequence these agents based on approval parameters from the FDA, but this may not be the best way
  • Physicians need to understand more about the biology and cross-resistance patterns of these agents and how to integrate rational combinations with limited toxicities in order to improve sequencing techniques